ClinicalTrials.gg
CompletedNCT00998296Updated Aug 19, 2015Results posted

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

A Phase 1 interventional study of BIBW 2992 and BIBF 1120 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this trial is to determine the Maximum Tolerated Dose (MTD) of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly. The MTD will provide dosing recommendation for subsequent phase II trials in patients with metastatic cancer.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 70 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed histological or cytological diagnosis of advanced solid tumours and for whom no proven therapy exists or who are not amenable to established treatments.
  2. Age 18 years or older.
  3. of at least three months.
  4. (ECOG) performance score 0 or 1.
  5. Patients previously treated and with asymptomatic are eligible
  6. Patients must have recovered from recent surgery.

Exclusion criteria

Exclusion criteria:

  1. Active infectious disease
  2. Recent surgery within the last 4 weeks prior visit 1.
  3. Chronic diarrhoea or gastrointestinal tract disease resulting in an inability to take oral medication
  4. History of haemorrhagic or thrombotic events
  5. Significant cardiovascular diseases within
  6. Current peripheral neuropathy > (CTCAE) grade 1 except due to trauma
  7. Untreated or symptomatic or .
  8. Treatment with an Epidermal growth Factor-receptor (EGFR)- or Heregulin Receptor 2 () inhibiting drug or antiangiogenic drug.
  9. Therapeutic anticoagulation.
  10. Female patients of .
  11. Known pre-existing interstitial lung disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    BIBW 2992 + BIBF 1120

    This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.

    Drug: BIBW 2992 · Drug: BIBF 1120

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities

    Maximum tolerated dose (MTD) of nintedanib and afatinib based on the Percentage of participants experienced dose limiting toxicities during the dose escalation phase.

    Time frame: first treatment cycle, up to 28 days

Secondary outcomes

  1. Overall Tumour Response Rate Assessed by the Investigator According to the Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1

    The investigator evaluated whether complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) occurred in a patient. CR for target lesions: Disappearance of all target lesions. CR for non-target lesions: Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (\<10mm short axis). PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions

    Time frame: 6 weeks

  2. Incidence and Intensity of Adverse Events According to CTCAE (Common Toxicity Criteria Adverse Event) Version 3.0

    Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).

    Time frame: First treatment administration until cut-off date of 02Oct2014; up to 336 days

  3. Changes in Safety Laboratory Parameters

    Changes in safety laboratory Parameters reported as adverse events

    Time frame: First treatment administration until cut-off date of 02 October 2014, up to 336 days

  4. Cpre,ss,Norm (Dose Normalized Trough Plasma Concentration of Nintedanib at Steady State)

    Cpre,ss,norm (Dose normalized trough plasma concentration of nintedanib at steady state) are presented for the 2 MTD treatment groups (continuous administered nintedanib at 150 mg b.i.d. concomitantly with continuously administered afatinib 30 mg q.d. or with intermittently administered afatinib 40 mg q.d.) As nintedanib is given twice daily, samples are taken at Day 8, Day 15, Day 22 and Day 28; the Pharmacokinetic (PK) parameter names will be Cpre,ss,15,norm (Day 8), Cpre,ss,29,norm (Day 15), Cpre,ss,43,norm (Day 22) and Cpre,ss,55,norm (Day 28)

    Time frame: Day 8, Day 15, Day 22 and Day 28

  5. Trough Plasma Concentration of Afatinib at Steady State

    C(pre,ss) is defined as pre-dose (trough) concentration of afatinib in plasma at steady state immediately before administration of the next dose. C24,7 corresponds to the plasma concentration at 24 hours on Day 7. C24,13 corresponds to the plasma concentration at 24 hours on Day 13. C24,27 corresponds to the plasma concentration at 24 hours on Day 27.

    Time frame: Day 7, Day 13, Day 15, Day 22, Day 27 and Day 28

  6. Objective Response (OR) During the Expansion Phase

    OR is defined as a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1, CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size (\<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below: CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; All the above scenarios should also satisfy 'No occurrence of new lesions'.

    Time frame: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)

  7. Disease Control (DC) During the Expansion Phase

    DC is defined as the best overall response of CR, PR, stable disease (SD) and non-CR/non-PD. CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions . All lymph nodes must be non-pathological in size (\<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below:- CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; SD for TL: change in the sum of diameters does not satisfy PR or PD. SD in TL, non-PD in NTL lead to overall response of SD, provided there is no appearance of new lesions.

    Time frame: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)

  8. Stable Disease for at Least 12 Weeks During the Expansion Phase

    SD: Neither sufficient shrinkage to qualify for PR (Partial response) nor sufficient increase to qualify for PD(Progressive disease), taking as references the smallest sum of diameters SoD while on study. PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.

    Time frame: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)

  9. Percentage Change in the Tumour Size From Baseline During the Expansion Phase

    Percentage change in the tumour size from baseline is expressed as Number of subjects with maximum decrease from baseline in the sum of longest diameters of target lesions.

    Time frame: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)

07

Results

Posted Feb 9, 2015
Limitations and caveats
Statistics of PK parameters are only estimated when at least 2/3 of the data are evaluable.

Participant flow

Trial consisted of a dose-escalation phase (to determine the maximum tolerated dose (MTD) of treatments administered concomitantly) and an expansion phase(to assess the safety and the preliminary anti-tumour activity of the combination therapy at the previously determined MTD in patients with non-small cell lung cancer or pancreatic adenocarcinoma)

Participant flow — Overall Study
MilestoneNintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuouslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - IntermittentlyNSCLCPancreatic Adenocarcinoma
Started633383766187
Completed62336364400
Not completed010020122187
Withdrew: Progressive disease010000100145
Withdrew: Dose limiting or dose reducing toxicity00001002200
Withdrew: Other adverse event00001000012
Withdrew: Refused to continue taking trial med.00000000020
Withdrew: Reason other than those specified above00000000010

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities

Maximum tolerated dose (MTD) of nintedanib and afatinib based on the Percentage of participants experienced dose limiting toxicities during the dose escalation phase.

Time frame:
first treatment cycle, up to 28 days
Reported as:
Number · percentage of participants
Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities
percentage of participantsNintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuouslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - Intermittently
Alanine aminotransferase increased0.00.00.00.012.533.30.00.00.0
Aspartate aminotransferase increased0.00.00.00.012.50.00.00.00.0
Blood creatinine increased0.00.00.00.00.033.30.016.70.0
Dehydration0.033.30.00.00.00.00.00.016.7
Diarrhoea0.033.30.00.025.033.30.016.70.0
Hepatocellular injury0.00.00.00.00.033.30.016.70.0
Renal failure acute0.066.70.00.00.00.00.00.00.0
Hepatotoxicity0.00.00.00.00.00.00.00.016.7
SecondaryOverall Tumour Response Rate Assessed by the Investigator According to the Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1

The investigator evaluated whether complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) occurred in a patient. CR for target lesions: Disappearance of all target lesions. CR for non-target lesions: Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (\<10mm short axis). PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions

Time frame:
6 weeks
Reported as:
Number · percentage of participants
Overall Tumour Response Rate Assessed by the Investigator According to the Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1
percentage of participantsNintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuouslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - IntermittentlyNSCLCPancreatic Adenocarcinoma
Complete response0.00.00.00.00.00.00.00.00.00.00.0
Partial response0.00.00.00.00.00.00.00.00.017.60.0
Stable disease66.766.766.733.371.410066.783.3100.070.633.3
Progressive disease33.333.333.366.728.60.033.316.70.011.866.6
SecondaryIncidence and Intensity of Adverse Events According to CTCAE (Common Toxicity Criteria Adverse Event) Version 3.0

Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).

Time frame:
First treatment administration until cut-off date of 02Oct2014; up to 336 days
Reported as:
Number · participants
Incidence and Intensity of Adverse Events According to CTCAE (Common Toxicity Criteria Adverse Event) Version 3.0
participantsNintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuouslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - IntermittentlyNSCLCPancreatic Adenocarcinoma
CTCAE Grade 110000010001
CTCAE Grade 220121024072
CTCAE Grade 312215242372
CTCAE Grade 420001100222
CTCAE Grade 501001000120
SecondaryChanges in Safety Laboratory Parameters

Changes in safety laboratory Parameters reported as adverse events

Time frame:
First treatment administration until cut-off date of 02 October 2014, up to 336 days
Reported as:
Number · participants
Changes in Safety Laboratory Parameters
participantsNintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuouslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - IntermittentlyNSCLCPancreatic Adenocarcinoma
Alanine aminotransferase increased11113313311
Aspartate aminotransferase increased11103312112
Blood creatinine increased10001111110
Blood alkaline phosphatase increased01101001000
Blood bilirubin increased00100100002
Troponin increased01000000000
Gamma-glutamyltransferase increased00000041000
Blood creatinine phosphokinase increased00010000000
Blood fibrinogen increased00010010000
Hepatic enzymes increased00000000100
SecondaryCpre,ss,Norm (Dose Normalized Trough Plasma Concentration of Nintedanib at Steady State)

Cpre,ss,norm (Dose normalized trough plasma concentration of nintedanib at steady state) are presented for the 2 MTD treatment groups (continuous administered nintedanib at 150 mg b.i.d. concomitantly with continuously administered afatinib 30 mg q.d. or with intermittently administered afatinib 40 mg q.d.) As nintedanib is given twice daily, samples are taken at Day 8, Day 15, Day 22 and Day 28; the Pharmacokinetic (PK) parameter names will be Cpre,ss,15,norm (Day 8), Cpre,ss,29,norm (Day 15), Cpre,ss,43,norm (Day 22) and Cpre,ss,55,norm (Day 28)

Time frame:
Day 8, Day 15, Day 22 and Day 28
Reported as:
Geometric mean · nanogram/millilitre/milligram (ng/mL/mg)
Cpre,ss,Norm (Dose Normalized Trough Plasma Concentration of Nintedanib at Steady State)
nanogram/millilitre/milligram (ng/mL/mg)Nintedanib 150 mg +Afatinib 30 mg- ContinuouslyNintedanib 150 mg +Afatinib 40 mg- Intermittently
Cpre,ss,15,norm (N= 6, 7)0.122 ± 1550.0731 ± 92.2
Cpre,ss,29,norm (N= 6, 6)0.0948 ± 1360.0755 ± 148
Cpre,ss,43,norm (N= 5, 6)0.112 ± 1250.0762 ± 79.7
Cpre,ss,55,norm (N= 8, NA)0.0797 ± 247NA ± NA
SecondaryTrough Plasma Concentration of Afatinib at Steady State

C(pre,ss) is defined as pre-dose (trough) concentration of afatinib in plasma at steady state immediately before administration of the next dose. C24,7 corresponds to the plasma concentration at 24 hours on Day 7. C24,13 corresponds to the plasma concentration at 24 hours on Day 13. C24,27 corresponds to the plasma concentration at 24 hours on Day 27.

Time frame:
Day 7, Day 13, Day 15, Day 22, Day 27 and Day 28
Reported as:
Geometric mean · nanogram/millilitre (ng/mL)
Trough Plasma Concentration of Afatinib at Steady State
nanogram/millilitre (ng/mL)Nintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - Intermittently
Cpre,ss,15 (N= 6, NA)15.5 ± 62.0NA ± NA
Cpre,ss,22 (N= 6, NA)19.0 ± 56.5NA ± NA
Cpre,ss,28 (N= 8, NA)19.1 ± 63.3NA ± NA
C24,7 (N= NA, 6)NA ± NA19.6 ± 127.0
C24,13 (N= NA, 5)NA ± NA11.5 ± 76.4
C24,27 (N= NA, 2)NA ± NA30.5 ± 21.9
SecondaryObjective Response (OR) During the Expansion Phase

OR is defined as a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1, CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size (\<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below: CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; All the above scenarios should also satisfy 'No occurrence of new lesions'.

Time frame:
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
Reported as:
Number · percentage of participants
Objective Response (OR) During the Expansion Phase
percentage of participantsNSCLCPancreatic Adenocarcinoma
Yes22.20.0
No72.285.7
Missing5.614.3
SecondaryDisease Control (DC) During the Expansion Phase

DC is defined as the best overall response of CR, PR, stable disease (SD) and non-CR/non-PD. CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions . All lymph nodes must be non-pathological in size (\<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below:- CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; SD for TL: change in the sum of diameters does not satisfy PR or PD. SD in TL, non-PD in NTL lead to overall response of SD, provided there is no appearance of new lesions.

Time frame:
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
Reported as:
Number · percentage of participants
Disease Control (DC) During the Expansion Phase
percentage of participantsNSCLCPancreatic Adenocarcinoma
Yes83.328.6
No11.157.1
Missing5.614.3
SecondaryStable Disease for at Least 12 Weeks During the Expansion Phase

SD: Neither sufficient shrinkage to qualify for PR (Partial response) nor sufficient increase to qualify for PD(Progressive disease), taking as references the smallest sum of diameters SoD while on study. PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.

Time frame:
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
Reported as:
Number · percentage of participants
Stable Disease for at Least 12 Weeks During the Expansion Phase
percentage of participantsNSCLCPancreatic Adenocarcinoma
Yes44.40.0
No50.085.7
Missing5.614.3
SecondaryPercentage Change in the Tumour Size From Baseline During the Expansion Phase

Percentage change in the tumour size from baseline is expressed as Number of subjects with maximum decrease from baseline in the sum of longest diameters of target lesions.

Time frame:
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
Reported as:
Number · participants
Percentage Change in the Tumour Size From Baseline During the Expansion Phase
participantsNSCLCPancreatic Adenocarcinoma
>=20%13
>=0% and <20%43
>-30% and <0%60
<-30%50

Adverse events

Collected over First treatment administration until cut-off date of 02Oct2014; up to 336 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib 150 mg +Afatinib 30 mg - Continuously—3/6 (50%)6/6 (100%)
Nintedanib 150 mg +Afatinib 40 mg - Continuously—3/3 (100%)3/3 (100%)
Nintedanib 200 mg +Afatinib 10 mg - Continuously—1/3 (33.3%)3/3 (100%)
Nintedanib 200 mg +Afatinib 20 mg - Continuosly—0/3 (0%)3/3 (100%)
Nintedanib 200 mg +Afatinib 30 mg - Continuously—7/8 (87.5%)8/8 (100%)
Nintedanib 200 mg +Afatinib 40 mg - Continuously—3/3 (100%)3/3 (100%)
Nintedanib 150 mg +Afatinib 40 mg - Intermittently—1/7 (14.3%)7/7 (100%)
Nintedanib 200 mg +Afatinib 30 mg - Intermittently—1/6 (16.7%)6/6 (100%)
Nintedanib 200 mg +Afatinib 40 mg - Intermittently—4/6 (66.7%)6/6 (100%)
NSCLC—7/18 (38.9%)18/18 (100%)
Pancreatic Adenocarcinoma—3/7 (42.9%)6/7 (85.7%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventNintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuoslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - IntermittentlyNSCLCPancreatic Adenocarcinoma
DiarrhoeaGastrointestinal disorders2/60/30/30/33/81/31/71/60/62/181/7
HyperthermiaGeneral disorders0/61/30/30/30/80/30/70/60/60/180/7
Oedema peripheralGeneral disorders0/60/30/30/30/81/30/70/60/60/180/7
Bile duct obstructionHepatobiliary disorders0/60/31/30/30/80/30/70/60/60/180/7
CholangitisHepatobiliary disorders0/61/31/30/30/81/30/70/60/60/180/7
CholecystitisHepatobiliary disorders0/61/30/30/30/80/30/70/60/60/180/7
Blood creatinine increasedInvestigations0/60/30/30/30/81/30/71/60/60/181/7
DehydrationMetabolism and nutrition disorders2/60/30/30/31/80/30/71/60/62/180/7
Ischaemic strokeNervous system disorders0/61/30/30/30/80/30/70/60/60/180/7
Renal failure acuteRenal and urinary disorders0/60/30/30/30/81/30/70/62/60/180/7
Most frequent other events
Showing 10 of 225
Most frequent other events
EventNintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuoslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - IntermittentlyNSCLCPancreatic Adenocarcinoma
Aphthous stomatitisGastrointestinal disorders0/61/30/30/31/83/30/70/61/60/180/7
DiarrhoeaGastrointestinal disorders6/63/33/33/38/83/36/76/66/614/186/7
NauseaGastrointestinal disorders4/63/32/33/34/82/34/73/65/612/183/7
VomitingGastrointestinal disorders1/63/31/32/35/83/33/75/65/66/180/7
AstheniaGeneral disorders6/63/32/33/38/83/35/72/63/613/182/7
FolliculitisInfections and infestations4/63/30/32/34/81/34/72/63/60/180/7
RhinitisInfections and infestations3/61/33/33/34/82/31/70/62/65/181/7
Alanine aminotransferase increasedInvestigations1/61/31/31/32/83/31/73/63/61/181/7
Aspartate aminotransferase increasedInvestigations1/61/31/30/32/83/31/72/61/61/182/7
Decreased appetiteMetabolism and nutrition disorders3/63/31/32/33/83/34/76/64/611/182/7

Baseline characteristics

Treated Set (TS): A treated set (TS) was defined consisting of all patients who received at least one dose of nintedanib or afatinib during the study period.

Age, Continuous
Age, Continuous(years)Nintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuouslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - IntermittentlyNSCLCPancreatic AdenocarcinomaTotal
Mean53.7 ± 8.151.7 ± 1.546.7 ± 4.953.3 ± 11.051.5 ± 9.744.3 ± 8.164.9 ± 3.552.2 ± 6.063.3 ± 10.358.1 ± 10.958.1 ± 6.856.0 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Nintedanib 150 mg +Afatinib 30 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - ContinuouslyNintedanib 200 mg +Afatinib 10 mg - ContinuouslyNintedanib 200 mg +Afatinib 20 mg - ContinuouslyNintedanib 200 mg +Afatinib 30 mg - ContinuouslyNintedanib 200 mg +Afatinib 40 mg - ContinuouslyNintedanib 150 mg +Afatinib 40 mg - IntermittentlyNintedanib 200 mg +Afatinib 30 mg - IntermittentlyNintedanib 200 mg +Afatinib 40 mg - IntermittentlyNSCLCPancreatic AdenocarcinomaTotal
Female31016204211131
Male3232217247639
08

Study locations

1 site
  • 1239.14.3301A Boehringer Ingelheim Investigational Site
    Villejuif Cedex, France
09

References and documents

Publications

  • Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E, Amellal N, Farace F, Ould-Kaci M, Roux F, Marzin K, Soria JC. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Br J Cancer. 2015 Nov 17;113(10):1413-20. doi: 10.1038/bjc.2015.374. Epub 2015 Oct 29. PubMed 26512876 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Dec 2012 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2009
First posted
Oct 20, 2009
Start
Oct 2009
Primary completionActual
Dec 2012
CompletionActual
Jul 2014
Results first posted
Feb 9, 2015
Last update
Aug 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00998296
Responsible party
Sponsor
First posted
Oct 20, 2009
Start date
Oct 2009
Primary completion
Dec 2012
Completion
Jul 2014
Results posted
Feb 9, 2015
Last update
Aug 19, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Afatinib · Nintedanib

Start the discussion